Multiple sclerosis, an autoimmune condition affecting the protective covering of nerve cells, impairs the transmission of electrical signals from the brain needed for muscle control and movement. Fampridine, described as a signal booster, works by helping these electrical messages reach their targets despite the damage caused by the disease.
Clinical trials demonstrated that approximately four in 10 people taking fampridine experienced improvements in walking speed and endurance. The NHS has decided to make the drug available in England after previously determining it did not represent adequate value for money. The medication is already available in Wales, Scotland, and Northern Ireland.
Estimates suggest up to 5,000 people in England could benefit from fampridine annually, though more than 120,000 individuals live with multiple sclerosis in the country. Eligibility will depend on the severity of walking difficulties. The treatment will be subject to a trial period of up to one month, with continued access limited to patients showing clear clinical benefit.
Healthcare officials noted that even modest improvements in mobility could enable patients to move around their homes more easily, engage in social activities with greater confidence, and maintain greater independence. Patient advocates emphasized the potential for the drug to help individuals remain employed and sustain independence in daily life.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI